Management of pulmonary arterial hypertension in systemic sclerosis: from classical treatments to new horizons - PubMed
2 days ago
- #Pulmonary Arterial Hypertension
- #Treatment Strategies
- #Systemic Sclerosis
- Pulmonary arterial hypertension (PAH) is a severe disease characterized by progressive thickening and obliteration of pulmonary vessels, leading to increased vascular resistance, elevated pulmonary artery pressures, and right heart failure.
- Systemic sclerosis (SSc) is the most common condition associated with PAH in Western countries, with SSc-PAH presenting a more aggressive clinical course, poorer response to conventional therapies, and worse prognosis compared to other forms of PAH.
- Despite similarities in management between SSc-PAH and idiopathic PAH, there is a crucial need for treatment strategies specifically tailored to SSc-PAH.
- A systematic literature review assessed the evidence on SSc-PAH management, covering conventional therapies, immunosuppressants, nonconventional drugs, and surgical/interventional procedures.
- Key gaps identified include the lack of studies focusing on SSc-PAH, heterogeneity in hemodynamic severity (with scarce data for mild PAH), and exclusion of relevant comorbidities like interstitial lung disease.
- Pragmatic, experience-based suggestions are provided to help clinicians manage SSc-PAH, especially in cases where robust data are lacking.